PLERIXAFOR IN THE TREATMENT OF STEM CELL MOBILIZATION FAILURE; FIRST EXPERIENCE IN IRAN

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MEHDIZADEH MAHSHID; HAJIFATHALI ABBAS; TABARAIE MAHDI; TAVAKOLI ARDAKANI MARIA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Pharmaceutical Research Year:2013 | Volume:12 | Issue:SUPPLEMENT 1 Page(s): 189-191

Download Full-Text

View:

353

Download:

146

Cites:

Information Journal Paper

Title

PLERIXAFOR IN THE TREATMENT OF STEM CELL MOBILIZATION FAILURE; FIRST EXPERIENCE IN IRAN

Author(s)

MEHDIZADEH MAHSHID | HAJIFATHALI ABBAS | TABARAIE MAHDI | TAVAKOLI ARDAKANI MARIA | Issue Writer Certificate

Keywords

PLERIXAFOR

MOBILIZATION

STEM CELL TRANSPLANT

Abstract

High-dose chemotherapy and autologous STEM CELL TRANSPLANTation (SCT) have become an effective care for many patients with hematological malignancies. Harvesting the stem cells is one the most important parts of SCT. The two most commonly used MOBILIZATION regimens are the use of granulocyte colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy. However, about 10-30% of patients are unable to collect enough cells to support HSCT dueto previous chemotherapies, radiation, marrow involvement or fibrosis. In multiple myeloma patients, it is hard to collect enough stem cells when the bone marrow is extensively involved. PLERIXAFOR has emerged as a novel mobilizing agent and its efficacy has been shown in two phase III studies. Considering the importance of autologous SCT in patients with multiple myeloma, we report the first successful Iranian experience at Tehran Taleghani bone marrow transplantation center using PLERIXAFOR to mobilize stem cells in a patient with refractory multiple myeloma with extensive bone marrow involvement who failed MOBILIZATION with G-CSF.

Cites

No record.

References

No record.

Cite

APA: Copy

MEHDIZADEH, MAHSHID, HAJIFATHALI, ABBAS, TABARAIE, MAHDI, & TAVAKOLI ARDAKANI, MARIA. (2013). PLERIXAFOR IN THE TREATMENT OF STEM CELL MOBILIZATION FAILURE; FIRST EXPERIENCE IN IRAN. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 12(SUPPLEMENT 1), 189-191. SID. https://sid.ir/paper/288047/en

Vancouver: Copy

MEHDIZADEH MAHSHID, HAJIFATHALI ABBAS, TABARAIE MAHDI, TAVAKOLI ARDAKANI MARIA. PLERIXAFOR IN THE TREATMENT OF STEM CELL MOBILIZATION FAILURE; FIRST EXPERIENCE IN IRAN. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2013;12(SUPPLEMENT 1):189-191. Available from: https://sid.ir/paper/288047/en

IEEE: Copy

MAHSHID MEHDIZADEH, ABBAS HAJIFATHALI, MAHDI TABARAIE, and MARIA TAVAKOLI ARDAKANI, “PLERIXAFOR IN THE TREATMENT OF STEM CELL MOBILIZATION FAILURE; FIRST EXPERIENCE IN IRAN,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 12, no. SUPPLEMENT 1, pp. 189–191, 2013, [Online]. Available: https://sid.ir/paper/288047/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops